泊洛妥珠單抗

{{Infobox drug
| drug_name =
| INN =
| type = mab
| image = Vedotin_ADCs.svg
| image_class = skin-invert-image
| alt =
| caption =

| mab_type = mab
| source = zu/o
| target =

| pronounce =
| tradename = Polivy
| Drugs.com =
| MedlinePlus = a619039
| licence_EU = yes
| DailyMedID = Polatuzumab vedotin
| pregnancy_AU = D
| pregnancy_AU_comment =
| legal_BR =
| legal_BR_comment =
| legal_CA = Rx-only
| legal_CA_comment = / Schedule D
| legal_DE =
| legal_DE_comment =
| legal_NZ =
| legal_NZ_comment =
| legal_UK = POM
| legal_UK_comment =
| legal_US = Rx-only
| legal_US_comment =
| legal_EU = Rx-only
| legal_EU_comment = 。

最常見的副作用包括白血球下降、）及紅血球數量減少；神經損傷（）；疲倦、腹瀉、發燒、食慾下降及肺炎，2019年10月獲准在澳洲使用，並於2020年11月獲准在加拿大使用。

參考文獻
延伸閱讀
*
*
*
*

外部連結
*
*